Content Type: Policy Interactions

Testimony: Reauthorization of MDUFA: What It Means for Jobs, Innovation, and Patients

April 8, 2026

Testimony: 21st Century Cures: Modernizing Clinical Trials

April 8, 2026

Testimony: The Public Health Risks of Expanding Off-Label Promotion of Prescription Drugs and Devices

April 8, 2026

Testimony: Strategies that Delay Timely Generic Entry of Generic Drugs and Potential Policy Solutions: The CREATES Act and Beyond

April 8, 2026

Testimony: Origins of and Solutions to High Drug Prices in the US

April 8, 2026

Testimony: High US Prescription Drug Prices: Anatomy of the Problem and Prospects for Reform

April 8, 2026

Testimony: More Cures for More Patients: Overcoming Barriers

April 8, 2026

Testimony: Drug Approval During the COVID-19 Pandemic: Following the Evidence

April 8, 2026

Testimony: Congress Should Support Development of New Treatments for Pediatric Rare Diseases, But Not with Priority Review Vouchers

April 8, 2026

Testimony: Addressing Pharmaceutical Patent Abuses Could Lower Drug Spending and Improve Patient Outcomes

April 8, 2026

Testimony: How the US Government Supports Meaningful Drug and Device Innovation: Funding Development of Transformative Therapies and Avoiding Excessing Prices for New Products with Limited Benefits

April 8, 2026

Testimony: Causes of Unaffordable Prescription Drugs: Monopolies, Rebates, and Misaligned Incentives

April 8, 2026